Search
for
Sort by
Research 121–150 of 775
- Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib
- Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
- 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata
- Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
- Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- Alopecia areata treatment with baricitinib: different relapse phenotypes
- Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- Hair growth–promoting effects of Enz_MoriL on human dermal papilla cells through modulation of the Wnt/β-Catenin and JAK-STAT signaling pathways
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- A new era for alopecia areata: New treatments and improved knowledge of the condition
- Keratin 6A promotes skin inflammation through JAK1-STAT3 activation in keratinocytes
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Baricitinib for Alopecia Universalis Following Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms
- Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- The role of janus kinases in the treatment of autoimmune skin diseases
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Tofacitinib for the treatment of lichen planopilaris: A case series